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Background: Scleroderma (SSc) is a complex autoimmune disorder that can be characterised by the presence
2of circulating autoantibodies to nuclear, cytoplasmic and cell surface antigens. In particular antibodies directed
against endothelial cell antigens (anti-endothelial cell antibodies; AECA) have been detected.
ICAM-1 is an adhesion molecule expressed on the surface of human endothelial cells. We have previously
shown that cross-linking ICAM-1 with monoclonal antibodies leads to pro-inﬂammatory activation of human
endothelial and vascular smooth muscle cells and that cardiac transplant recipients with transplant associated
vasculopathy make antibodies directed against ICAM-1.
Objectives: To determine whether SSc patients make antibodies directed against ICAM-1 and whether these
antibodies induce pro-inﬂammatory activation of human endothelial cells in vitro.
Methods: Using recombinant ICAM-1 as capture antigen, an ELISA was developed to measure ICAM-1 antibodies
in sera from SSc patients. Antibodieswere puriﬁed using ICAM-1micro-afﬁnity columns. HUVECwere incubated
with puriﬁed anti-ICAM-1 antibodies and generation of reactive oxygen species, and expression of VCAM-1 was
measured.
Results: Signiﬁcantly elevated levels of anti-ICAM-1 antibodies were detected in patients with diffuse (dSSc; 10/31
32%) or limited (lSSc; 14/36 39%) scleroderma. Cross-linkingofHUVECwith puriﬁed anti-ICAM-1 antibodies caused
a signiﬁcant increase in ROS production (2.471 ± 0.408 fold increase above untreated after 150 min p b 0.001),
and signiﬁcant increase in VCAM-1 expression (10.6 ± 1.77% vs 4.12 ± 1.33%, p b 0.01).
Conclusion: AECA from SSc patients target speciﬁc endothelial antigens including ICAM-1, and cause
pro-inﬂammatory activation of human endothelial cells, suggesting that they are not only a marker of disease
but that they contribute to its progression.© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY license.1. Introduction
1.1. Scleroderma and autoantibodies
Scleroderma or systemic sclerosis (SSc), is an autoimmune connec-
tive tissue disorder that targets ﬁbroblasts and the vascular endotheli-
um. Limited SSc (lSSc) affects mainly the skin of the hands, face and
arms, although pulmonary arterial hypertension may also be a serious
complication. Diffuse SSc (dSSc) is the rapidly progressing form of the
disease, characterised by severeﬁbrosis of large areas of skin and viscer-
al organs, as well as widespread vascular injury (Kao and Weyand,ation Biology within Lifestyle
Sciences, The Royal Veterinary
+44 207 468 1216; fax: +44
e British Heart Foundation.
sociation, project grant KC/01.
nc. Open access under CC BY license.2010). Although the underlying pathologic triggers remain elusive,
there is evidence for expansion of circulating B cells in SSc patients
(Sato et al., 2004), altered T cell responses leading to a Th2 cytokinemi-
lieu (Gabrielli et al., 2007; Hasegawa et al., 1997; Hasegawa et al., 1998),
and there aremany reports describing the presence of autoantibodies in
serum from these patients (review (Mihai and Tervaert, 2010)).
Anti-endothelial cell antibodies (AECA) were ﬁrst described in the
literature more than 40 years ago (review (Gabrielli et al., 2007)) in
sera from patients with a number of different rheumatic diseases.
AECA appear to recognise a number of different endothelial epitopes,
including cell surface, cytoplasmic and nuclear antigens, and there is
increasing evidence that at least some species may have agonistic
properties i.e. they appear to cause endothelial cell activation and
therefore are hypothesised to contribute to disease progression.
1.2. Agonistic anti-ICAM-1 antibodies
ICAM-1 is a 90 kDa Ig superfamily protein, expressed on the surface
of several cell types including endothelial cells, where it has been
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migration of several leukocyte subsets. ICAM-1 itself can activate cell
signalling cascades after receptormultimerisationwhich can be achieved
in vitro by co-culturing of EC with LFA-1 positive leukocytes, artiﬁcial
clustering of ICAM-1 on EC by ﬁbrinogen, or cross-linking with
anti-ICAM-1 antibodies (review (Hubbard and Rothlein, 2000; Lawson
and Wolf, 2009)).
A number of signalling molecules and adapter proteins have been
linked with the ICAM-1 signalling cascade in vitro, depending on cell
lineage or origin of vascular bed of EC used, and the experimental
model (for review see (Lawson and Wolf, 2009)). Cross-linking of
ICAM-1 on the cell surface of endothelial cells leads to its redistribu-
tion from the detergent soluble to insoluble fraction, suggesting that
it is involved with endothelial cytoskeletal rearrangements required
for leukocyte emigration (Amos et al., 2001). A number of studies
have also demonstrated that ICAM-1 cross-linking, either with mono-
clonal antibodies or during co-culture of endothelial cells with T cells,
leads to activation of molecules involved in these rearrangements in-
cluding Rho-A, a small GTPase responsible for actin stress ﬁbre forma-
tion (for review see (Lawson and Wolf, 2009)).
In addition to its role in actin cytoskeleton rearrangements, cross-
linking of ICAM-1 with monoclonal antibodies has also been shown to
activate pro-inﬂammatory cascades, via activation of MAPK kinases
ERK-1/2 and/or JNK (Etienne et al., 1998; Lawson et al., 1999; Sano
et al., 1998). Activation of ERK-1 leads to AP-1 activation (Lawson et
al., 1999) and ERK-dependent production and secretion of IL-8 and
RANTES (Sano et al., 1998), expression of VCAM-1 expression on
the cell surface (Lawson et al., 1999; Lawson et al., 2001). ICAM-1
cross-linking also upregulates tissue factor production (Schmid
et al., 1995) and expression of proinﬂammatory cytokines including
IL-1β (Koyama et al., 1996).
We have previously identiﬁed agonistic anti-ICAM-1 antibodies
in serum from cardiac transplant recipients with chronic transplant
vasculopathy and shown that serum from these patients can activate
phosphorylation of p42/p44 Erk MAPK (Lawson et al., 2005). In the
present study we have identiﬁed anti-ICAM-1 antibodies present in
serum from patients with SSc signiﬁcantly above levels seen in healthy
volunteers. Using microafﬁnity columns we have puriﬁed IgG anti-
ICAM-1 antibodies from these patients and shown that they bind to
human umbilical vein endothelial cells (HUVEC) and activate reactive
oxygen species production and VCAM-1 expression.
2. Methods
2.1. Materials
All chemicals were from Sigma (Poole, Dorset, UK) unless other-
wise stated. All plastics and tissue culture plates and ﬂasks were
from Nunc (Fisher Scientiﬁc, Loughborough, UK). All tissue culture
consumables were from PAA (UK) except for endothelial growth sup-
plement (ECGS) from Sigma. Anti-VCAM-1 MAb clone 1.4C3 and
anti-ICAM-1 MAb clone 6.5B5 were gifts from Professor Dorian
Haskard (Imperial College, London). Secondary FITC or HRP conjugated
antibodies were from DAKO. Rabbit anti-mouse Ig (RAM) used to
cross-link 6.5B5 was from DAKO. Rabbit anti-human Ig (RAH) used to
cross-link patient antibodies was from Jackson Immunotech (Stratech,
Luton, UK). Recombinant human TNF was from Insight Biotechnology
(Wembley, London, UK).
2.2. Source of human sera
Sera were collected from 60 patients with scleroderma (n = 32
lSSc, n = 28 dSSc) and from 26 healthy controls. Sera were collected
at the Royal Free Hospital; Centre for Rheumatology, London, UK;
with the informed consent of the patient. Volunteers with SSc ful-
ﬁlled the criteria of the ACR for the diagnosis of SSc and ethicalapproval was obtained from the Royal Free Hospital ethical practices
sub-committee.
2.3. Preparation of recombinant ICAM-1
Recombinant human ICAM-1 was cloned into pET15b (Novagen,
MerckMillipore, Darmstadt, Germany) and puriﬁed from cultures of
BL21 E. coli using His-bind columns as described previously (Holder
et al., 2008).
2.4. ELISA
Puriﬁed recombinant human ICAM-1 (rhICAM-1) was coated onto
alternate rows of 96well Maxisorp ELISA plates (Nunc, Fisher Scientiﬁc,
Loughborough, UK) at a concentration of 2 μg per well in 150 μl
1 × PBS. The remaining wells were coated with 1 × PBS alone to mea-
sure non-speciﬁc binding of Ig to the microtitre plate. Plates were incu-
bated at 4 °C overnight. The following morning plates were washed 3
times in 1 × PBS 0.1% Tween-20 (PBST) and all wells were blocked for
1 h with 300 μl 5% non-fat milk powder PBS-T (Marvel-PBST), followed
by three washes in PBST. Patient samples were diluted 1:50 in
Marvel-PBST and added to rhICAM-1 coated and PBS coated wells
in triplicate at 100 μl/well. Samples were incubated for 2 h at room
temperature followed by three washes in PBST. Positive controls were
monoclonal anti-ICAM-1 6.5B5 at 10, 5, 2.5, 1.25 μg/ml (10 μg/ml
was used for calculation of ELISA RATIO, see below) and negative
controls were Marvel-PBST alone. Wells were incubated with 100 μl
HRP-conjugated rabbit-anti-human-IgG or IgM or HRP-conjugated-
rabbit-anti-mouse IgG as appropriate and incubated for 45 min at
room temperature, followed by three washes in PBST. 100 μl TMB
supersensitive substrate (Sigma) was added and plates were incu-
bated for 5 min at room temperature before the reaction was
stopped by addition of 50 μl 1 M H2SO4. Plates were read using a
Wallac 1410 plate reader at 450 nm. In order to normalise OD results
across multiple plates and with multiple batches of recombinant
ICAM-1, an “ELISA ratio” (ER) was used which was calculated
according to the equation:
ER ¼
½OD450serumIgboundtoICAM1coatedwells
−½OD450serumIgboundtoPBScoatedwells
½OD450 6:5B5 10 μg=mlð Þto ICAM1coatedwells
−½OD450 6:5B5 10 μg=mlð ÞboundtoPBScoatedwells:
Sera were deemed to contain a high titre of anti-ICAM-1 antibod-
ies if the ER was greater the mean ER + 3sd of the negative control
sera.
2.5. Puriﬁcation of ICAM-1 antibodies from human serum
Recombinant hICAM-1 was prepared as described above and
coupled to Pierce micro-afﬁnity columns according to the manufac-
turer's instructions (Fisher Scientiﬁc). Anti-ICAM-1 antibodies were
puriﬁed from 200 μl SSc patient serum (n = 6 patients) selected as
highly positive for anti-ICAM-1 as determined by our ELISA, and the
manufacturer's instructions were followed. All washes were kept for
use as negative controls. Puriﬁed antibodies were analysed using
the anti-ICAM-1 ELISA described above to determine the relative con-
centrations compared to the 6.5B5 positive control anti-ICAM-1 MAb,
to conﬁrm their presence (data not shown).
2.6. HUVEC isolation and culture
Human umbilical cords were collected from the Royal London
Hospital with ethical approval from the East London Research Ethics
Committee. Human umbilical vein endothelial cells (HUVEC) were
Fig. 1. Detection of anti-ICAM-1 antibodies in serum from SSc patients. Levels of anti-
ICAM-1 IgG and IgM antibodiesweremeasured in serum from60 patientswith scleroderma
(n = 32 LSSc, n = 28 DSSc) and from 26 healthy controls, using immobilised recombinant
human ICAM-1 as the capture antigen. *p b 0.05; **p b 0.01, Mann–Whitney tests com-
pared to healthy controls.
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medium (M199 supplemented with 20% FCS, 2 mM L-glutamine,
1× penicillin/streptomycin, 30 μg/ml ECGS from bovine neural tissue
and 1 unit/ml heparin) on 0.5% gelatin-coated tissue culture plates as
described previously (Lawson et al., 1999). Individual isolates of cells
were used at passage 3–5.
2.7. Analysis of binding of puriﬁed antibodies to HUVEC by ﬂow cytometry
HUVEC were plated onto gelatin coated 6 well plates at a density
of 2.5 × 105 cells per well. The following day the medium was re-
moved and replaced with M199/10% FCS for 4 h. After this time me-
dium was removed and replaced with M199/10% FCS containing
puriﬁed anti-ICAM-1 antibody, negative serum, wash buffer from an-
tibody puriﬁcation (all at 1:100 dilution), 10 ng/ml TNF or RAH Ig as
negative controls. Cells were incubated for 18 h. The following day
cells were trypsinised and washed with 1 × PBS followed by centri-
fugation at 405 xg to remove unbound antibodies. Cell pellets were
resuspended in 50 μl 1 × PBS with diluted FITC-conjugated goat-
anti-human IgG (1:100 from manufacturers stock), incubated for
30 min at 4 °C followed by a further wash with 1 × PBS and centrifu-
gation at 405 xg. Cell pellets were resuspended in 500 μl 0.5%formal-
dehyde/1 × PBS and analysed by ﬂow cytometry using a FACS
CANTO II. Post-acquisition analysis was carried out using FACS
DIVA software.
2.8. Measurement of reactive oxygen species (ROS) generation in HUVEC
after ICAM-1 cross-linking by puriﬁed anti-ICAM-1 antibodies
HUVEC were plated onto gelatin-coated white opaque 96 well
plates at a density of 2.5 × 104 cells per well in full HUVEC medium
with growth factor. The following day medium was removed and re-
placed with M199/10%FCS for 4 h. After this the medium was re-
moved from cells and replaced with 50 μl medium containing
5.7 μM dihydrorhodamine-1,2,3 (DHR), which acts as an indicator of
reactive oxygen species (ROS) production. DHR is taken up by live
cells and is not ﬂuorescent until it becomes oxidised in the presence
of intracellular peroxidases and intracellular H2O2 (Henderson and
Chappell, 1993). Cells were incubated for 10 min in the dark and
then treated with 50 μl puriﬁed anti-ICAM-1 antibody, whole fraction
of positive serum, washes from the puriﬁcation columns, or whole frac-
tion of negative serum as appropriate (all diluted 1:100 in M199/10%
FCS), for 10 min. After 10 min incubation the cross-linking rabbit-anti-
human Ig antibody (RAH; dilution 1:200; Jackson, Stratech, UK) was
added as appropriate (or 50 μl M199/10%FCS for non-cross-linked
wells) and plates were incubated at 37 °C. Fluorescence was measured
at t = 0, 10, 30, 60, 150 min using aWallac 1410ﬂuorescent plate reader
(FITC ﬁlter).
All treatments were carried out in triplicates using n = 2–6 sepa-
rate isolates of HUVEC to test n = 6 puriﬁed anti-ICAM-1 antibodies,
n = 6 whole serum, n = 3 negative serum, n = 3 wash from n = 3
separate puriﬁcations.
2.9. Analysis of VCAM-1 expression on HUVEC by ﬂow cytometry, after
ICAM-1 cross-linking by puriﬁed anti-ICAM-1 antibodies
HUVEC were plated onto gelatin coated 6 well plates at a density of
2.5 × 105 cells per well. The following day the medium was removed
and replaced with M199/10% FCS for 4 h. After this time medium was
removed and replaced with M199/10% FCS containing puriﬁed
anti-ICAM-1 antibody, negative serum,wash buffer from antibody puri-
ﬁcation or monoclonal 6.5B5 as appropriate. Cells were incubated for
30 min at 37 °C before the medium was removed and replaced with
medium containing rabbit anti-human IgG (RAH; 1:200 dilution;
Jackson, Stratech, UK) or rabbit anti-Mouse IgG (RAM; 1:200 dilution
Dako, UK) to cross-link cells for 18 h (6 h to 24 h for time courseexperiment). Incubation of HUVEC with 10 ng/ml rhTNF for 18 h
was used as a positive control. The following day cells were
trypsinised and washed with 1 × PBS followed by centrifugation
405 xg to pellet cells. Cell pellets were resuspended in 50 μl
1 × PBS with diluted anti-VCAM-1 MAb 1.4C3 as primary antibody,
(or with CRL1724 as a negative control; n = 2) incubated for
30 min at 4 °C and washed as above. Cell pellets were resuspended
in 50 μl FITC-conjugated goat-anti-human IgG (1:100 from
manufacturer's stock), incubated for 30 min at 4 °C and washed as
above. Cell pellets were resuspended in 500 μl 0.5%formaldehyde/
1 × PBS and analysed by ﬂow cytometry using a FACS CANTO II.
Post-acquisition analysis was carried out using FACS DIVA software.2.10. Statistical analysis
Graphpad Prism was used to analyse data. Data were analysed for
normal distribution using the D'Agostino–Pearson Omnibus normality
test. For normally distributed data 1 or 2 way ANOVA followed by
Bonferroni post-tests were used as appropriate. For non-parametric
data Mann–Whitney tests, Kruskal–Wallis ANOVA (unpaired data) or
a Friedman ANOVA (paired/repeated measures data) were performed,
followed by Dunns post-comparison tests. p b 0.05 was considered sta-
tistically signiﬁcant (*). Data are presented as mean + SEM.3. Results
3.1. Detection of antibodies to ICAM-1 in serum from SSc patients
The presence of immunoglobulins (IgM or IgG) able to bind to
immobilised recombinant human ICAM-1 was analysed in serum from
60 patients with scleroderma (n = 32 lSSc, n = 28 dSSc) and from
26 healthy controls. Signiﬁcantly elevated levels of anti-ICAM-1 anti-
bodies were detected in 10/31 (32%) patients with dSSc and 14/36
(39%) patients with lSSc, compared to normal control sera. As shown
in Fig. 1 levels of IgM against ICAM-1 were signiﬁcantly increased com-
pared to normal controls in both lSSc and dSSc patients (0.693 ± 0.082
lSSc; dSSc ER = 0.664 ± 0.093, both p b 0.01 compared to normal
controls ER 0.397 ± 0.075). The levels of anti-ICAM-1 of IgG subclass
were also increased in lSSc patients compared to normal controls
(ER 0.2781 ± 0.02 normal; 0.3962 ± 0.02 LSSc, p b 0.001 compared
to normal controls). Levels of anti-ICAM-1 IgG were not signiﬁcantly
22 S.I. Wolf et al. / Vascular Pharmacology 59 (2013) 19–26
Fig. 3. Puriﬁed anti-ICAM-1 antibodies induce reactive oxygen species production in
human endothelial cells. A. Puriﬁed anti-ICAM-1 antibodies (diluted 1:100), in the
presence or absence of crosslinking RAH antibody, were incubated with HUVEC had
been pre-loaded with dihydrorhodamine-1,2,3. Fluorescence was measured at regular
intervals up to 150 min. As negative controls HUVEC were treated with RAH alone,
negative serum (diluted 1:100) and RAH or wash buffer and RAH. *p b 0.05 ROS pro-
duction after incubation with puriﬁed ICAM-1 antibody and **p b 0.01, ***p b 0.001
ROS production after cross-linking of puriﬁed ICAM-1 antibody, compared to RAH
alone incubations, 2 way ANOVA with Bonferroni post-test (antibodies puriﬁed from
n = 6 patients). B. Puriﬁed anti-ICAM-1 antibodies, in the presence or absence of
crosslinking RAH antibody, were incubated with HUVEC had been pre-loaded with
dihydrorhodamine-1,2,3 at dilutions of 1:100, 1:250 or 1:500 ﬂuorescence wasmeasured
at 150 min. 2 way ANOVA with Bonferroni post-test $p b 0.05 ROS production after
incubation with puriﬁed ICAM-1 antibody at 1:100 dilution compared to 1:250 dilution
and $$$p b 0.001 compared to 1:500 dilution; ***p b 0.001 ROS production after
cross-linking of puriﬁed ICAM-1 antibody at 1:100 dilution compared to 1:250 or 1:500
dilution (antibodies puriﬁed from n = 4 patients).
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0.03).
3.2. Anti-ICAM-1 antibodies puriﬁed from SSc patients bind to HUVEC cell
surface
Anti-ICAM-1 antibodies were puriﬁed by microafﬁnity chroma-
tography from serum from six SSc patients with high reactivity to
ICAM-1, and binding of puriﬁed IgG to recombinant ICAM-1 in the pu-
riﬁed preparations was reafﬁrmed by anti-ICAM-1 ELISA (data not
shown). The ability of the puriﬁed anti-ICAM-1 antibodies to bind to
HUVEC cell surface was conﬁrmed by ﬂow cytometry (Fig. 2A). As
shown in Fig. 2B FITC-anti-human-IgG bound to 14.26 ± 1.95% of
cells that had been incubated for 18 h with anti-ICAM Ab puriﬁed from
SSc patients. In contrast, there was only binding of FITC-anti-human-
IgG to 4.53 ± 2.07% untreated cells (p b 0.01) or 5.75 ± 1.96% cells
pretreated with only the rabbit anti-human IgG cross-linking antibody
(RAH) (p b 0.05). In addition, using only anti-Human-IgF FITC we did
not detect any increase in ﬂuorescence of HUVEC which had been incu-
bated for 18 h with the whole fraction of serum previously shown to be
negative on our ICAM-1 ELISA (FITC-anti-human-IgG bound to 4.12 ±
1.83% cells), the wash buffer used during the afﬁnity puriﬁcation process
(FITC-anti-human-IgG bound to 2.16 ± 0.48% cells), or cells which had
been treated overnight with 10 ng/ml TNF (3.3 ± 1.4%). To conﬁrm
that TNF was able to increase ICAM-1 expression we stained TNF treated
HUVEC with anti-ICAM-1 6.5B5 followed by rabbit-anti-mouse-Ig-FITC
(Fig. 2C). These ﬁndings conﬁrm that the puriﬁed anti-ICAM-1 antibody
bound to a speciﬁc cell surface receptor rather than non-speciﬁc bind-
ing of the FITC-conjugated secondary anti-human-Ig to endothelial Fc
receptors.
3.3. Cross-linking of puriﬁed anti-ICAM-1 antibodies from SSc patients
leads to reactive oxygen species generation in HUVEC
Puriﬁed anti-ICAM-1 antibodies were allowed to bind to
dihydrorhodamine-1,2,3 loaded HUVEC followed by cross-linking with
RAH. Fluorescence was measured at regular intervals after initiation
of cross-linking. Signiﬁcant production of ROS was induced after
cross-linking HUVEC with the whole fraction of positive serum (3.45 ±
0.424 fold increase above untreated cells after 150 min p b 0.001) or pu-
riﬁed anti-ICAM-1 antibodies (2.471 ± 0.408 fold increase above
untreated after 150 min p b 0.001), when compared to cells treated
with RAH alone (0.927 ± 0.076 fold increase above untreated cells). In
contrast, there was no signiﬁcant increase in ROS production above RAH
alone treated cells in cells cross-linked with negative serum (1.437 ±
0.169) or with the wash fraction (0.93 ± 0.016) (Fig. 3A). To determine
whether there was a concentration dependent effect of antibody binding
on ROS production, increasing dilutions of puriﬁed patient anti-ICAM-1
antibodies (1:100, 1:250, 1:500) or wash fraction at similar dilutions
was incubated with DHR-loaded HUVEC for 150 min (Fig. 3B). ROS pro-
duction decreased signiﬁcantly with increased dilution of antibody
(2.060 ± 0.133 fold increase in ROS at 1:100 dilution compared to
1.729 ± 0.170 at 1:250 p b 0.05; and 1.18 ± 0.145 at 1:500 p b 0.001).
This was also the case after crosslinking with RAH (2.2356 ± 0.207 at
1:100 dilution compared to 2.058 ± 0.196 at 1:250 dilution p b 0.001
and 1.280 ± 0.134 at 1:500 dilution p b 0.001) (Fig. 3B).Fig. 2. Puriﬁed anti-ICAM-1 antibodies bind to human endothelial cells. Anti-ICAM-1 antib
HUVEC for 18 h at 37 °C, followed by conﬁrmation of their binding with a FITC-conjugate
additionally incubated with negative serum (diluted 1:100), wash buffer from the micro
10 ng/ml TNF, to conﬁrm that increase in ﬂuorescence was not due to non-speciﬁc bindin
FITC positive events. B. Graphs to show binding of puriﬁed antibodies from n = 6 patients
of HUVEC with 10 μg/ml TNF for 18 h followed by staining with 6.5B5 anti-ICAM-1 mous
puriﬁed Ab compared to all other overnight incubations, 1 way ANOVA followed by Bonfer3.4. Cross-linking of puriﬁed anti-ICAM-1 antibodies from SSc upregulates
VCAM-1 expression in HUVEC
Puriﬁed anti-ICAM-1 antibodies (1:100 dilution) were allowed to
bind to HUVEC, followed by cross-linking with RAH for between 6
and 24 h. HUVEC were trypsinised and VCAM-1 expression was
determined by ﬂow cytometry (Fig. 4A). There was a signiﬁcant in-
crease in VCAM-1 cell surface staining after incubation with puriﬁed
anti-ICAM-1 antibodies for 18 h with or without cross-linking, com-
pared to treatment of cells with RAH alone (9.69 ± 1.46% on
anti-ICAM-1 bound cells; 10.6 ± 1.77% on anti-ICAM-1 cross-linked
cells vs 4.12 ± 1.33% on RAH alone treated cells, p b 0.01 for each;
1 way ANOVA with Bonferroni post-test), however no increase was
observed after cross-linking with negative serum or with the wash
fraction (4.85 ± 0.73% and 4.51 ± 1.16% respectively) (see Fig. 4Aodies were puriﬁed from SSc patients using microafﬁnity columns and incubated with
d anti-human-IgG and analysis by ﬂow cytometry. As negative controls HUVEC were
afﬁnity puriﬁcation (diluted 1:100), rabbit-anti-human IgG (unconjugated; RAH) or
g via endothelial FcR. A. Representative histograms showing FITC staining. P2 denotes
and controls. C. Representative histogram to show ICAM-1 expression after incubation
e monoclonal antibody and rabbit-anti-mouse-Ig-FITC (n = 2). **p b 0.01 binding of
roni post-test.
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periment to determine the time course of VCAM-1 expression after
ICAM-1 cross-linking with puriﬁed antibodies, separate isolates
HUVEC were incubated for between 6 h and 24 h before staining for
VCAM-1 expression. VCAM-1 was elevated after 6 h incubation with
puriﬁed patient antibodies and remained signiﬁcantly elevated for
at least 24 h compared to HUVEC treated with the wash fraction
alone, with or without cross-linking with RAH (p b 0.001 Friedman
Test for non-parametric data and p b 0.05 Dunns post-test compari-
son crosslinked puriﬁed Ab 6 h compared to crosslinked puriﬁed Ab
12 h, 18 h, or 24 h; Fig. 4C). In a further experiment addition of de-
creasing concentrations of puriﬁed antibodies (1:100, 1:250, 1:500)
signiﬁcantly altered the level of VCAM-1 expression after 18 h incu-
bation (p b 0.05 Friedman repeated measures ANOVA for non-para-
metric data and p b 0.05 Dunns post-test comparison crosslinked
puriﬁed Ab diluted 1:100 compared to crosslinked puriﬁed Ab diluted
1:500; Fig. 4D).
4. Discussion
Here, we have developed a novel ELISA to detect the presence of
antibodies directed against ICAM-1 in the serum of patients with limited
and diffuse forms of SSc. We have puriﬁed anti-ICAM-1 antibodies from
serum and shown that they can induce pro-inﬂammatory signalling and
gene expression in human endothelial cells in vitro.
Antibodies directed against cell surface antigens on endothelial cells
(AECA) have been described in a number of autoimmune diseases,
including rheumatoid arthritis (Salih et al., 1999), lupus (Constans et al.,
2003), vasculitis (Salih et al., 1999), and SSc (Carvalho et al., 1996).
There is also a large literature on the presence of antibodies directed
against cytoplasmic or nuclear antigens in these patients (Cavazzana
et al., 2009; Moroi et al., 1980), some of which also appear to be against
endothelial antigens (Ahmed et al., 2006). AECA have likewise been
detected in patients with atherosclerosis (Farsi et al., 2001) and those
with vascular rejection of heart transplants (Fredrich et al., 1999). AECA
themselves have been shown to be damaging to endothelial cells in
vitro (Alessandri et al., 2006; Xia and Kellems, 2011) including
pro-apoptotic signalling (Ahmed et al., 2006; Hernandez et al., 2012;
Holmen et al., 2007). A number of studies have also shown associations
between the presence of AECA and increased morbidity, mortality or
cardiovascular complications, suggesting that the antibodies are agonistic
and contribute to endothelial dysfunction that is often associated with
autoimmune and chronic inﬂammatory diseases (Alessandri et al.,
2006; Mihai and Tervaert, 2010).
Although a number of previous publications have shown binding
of SSc sera to the cell surface or to cytoplasmic targets of HUVEC
this is the ﬁrst direct demonstration that one of the antibodies pro-
duced is against the 90 kDa adhesion molecule ICAM-1. Interestingly,
Ihn et al. previously identiﬁed a 90 kDa target for AECA from SSc pa-
tients although they showed that most binding was in the cytoplasm
of HUVEC (Ihn et al., 2000).
We and others have previously demonstrated that cross-linking
ICAM-1 on the surface of HUVEC or other endothelial cell tissue sourcesFig. 4. Puriﬁed anti-ICAM-1 antibodies induce VCAM-c1 expression on human endothelial
antibody, were incubated with HUVEC for 18 h at 37 °C followed by indirect immunoﬂuoresce
grams for stainingwith CRL1724 isotype control, RAH (negative control) treated cells, and cells
age of VCAM-1 positive HUVEC from n = 6 experiments after treatment with TNF (positive co
cross-linking (negative controls), or puriﬁed patient anti-ICAM-1 antibodies (diluted 1:100) w
ANOVA with Bonferroni post-test. Antibodies puriﬁed from n = 6 patients. C. Time course of V
1:100) with or without RAH cross-linking for 6, 12, 18, 24 h (n = 4), or VCAM-1 staining after
followed by Dunns post-test comparison *p b 0.05 crosslinked puriﬁed Ab 6 h compared to
anti-ICAM-1 antibodies (diluted 1:100; 1:250; 1:500) with or without RAH cross-linkin
(n = 2 HUVEC isolates) (Friedman ANOVA for non-parametric data followed by Dunns
crosslinked puriﬁed Ab diluted 1:500).leads to pro-inﬂammatory signal transduction (review (Lawson and
Wolf, 2009)). Here, we have recapitulated those ﬁndings after purifying
anti-ICAM-1 antibodies from scleroderma patients, and shown that
the puriﬁed antibodies bind to the cell surface of HUVEC, and after
cross-linking induce an increase in ROS generation and VCAM-1
expression.
Several studies from this group and others have shown that whole
serum with AECA activity or IgG fractions can similarly cause
upregulation of adhesion molecules (Carvalho et al., 1996; Del Papa
et al., 1996), whilst ﬁbroblasts from SSc patients have been shown
to produce more ROS than normal ﬁbroblasts after cytokine stimula-
tion (Sambo et al., 2001). Increased expression of ICAM-1 in skin and
circulating in the serum of SSc patients has been reported (Ihn et al.,
1997; Majewski et al., 1991), which could provide the initial stimulus
to break B cell tolerance to this widely expressed adhesion molecule.
It is interesting to note that while signiﬁcantly elevated levels of IgM
anti-ICAM-1 antibodies were detectable in both lSSc and dSSc patients,
elevated levels of IgG were only detectable in lSSc patients. Since lSSc is
a much less severe form of scleroderma, with less likelihood of vascular
involvement, one could postulate that these antibodiesmay have a pro-
tective or ameliorating effect on disease pathogenesis.
However, sincewe have also shownhere that the IgG fraction is able
to induce ROS production and VCAM-1 expression, which could be
thought to be likely to lead to enhancement of vascular inﬂammation,
elucidation of the exact nature of any protective effect requires further
analysis. We have preliminary data (not shown) to demonstrate that
the anti-ICAM-1 antibodies puriﬁed from scleroderma patients are
able to activate MAPK pathways in HUVEC, in agreement with our pre-
vious ﬁndings with monoclonal anti-ICAM-1 antibodies (Lawson et al.,
1999; Lawson et al., 2001). The pathways activated and the down-
stream biological effects are under further investigation. Our ﬁnding
that ROS production after ligation of ICAM-1 by puriﬁed SSc antibodies
with or without crosslinking was more sensitive to concentration effects
than VCAM-1 expression (Fig. 3B), suggests that there are altered sensi-
tivities in signal transduction pathways leading to VCAM-1 expression,
or expression of other pro-inﬂammatory or protective genes activated
via ROS, and will also be further investigated.
A limitation of use of HUVEC, or any non-transformed cells from a
range of different individuals, is that the behaviour of different isolates
may be altered. In this study the HUVEC isolates used to measure ex-
pression of VCAM-1 over a time course from 6 to 24 h appeared to be
more responsive than those used to measure the concentration effects
of the puriﬁed anti-ICAM-1 antibodies. This effect was also observed
when comparing the response of these isolates to TNF (Fig. 4C and D).
Interestingly, VCAM-1 expression after ICAM-1 cross-linking with pa-
tient puriﬁed antibodies at 1:100 dilution was always approximately
70% of that induced by TNF at 18 h in the same isolates.
In conclusion, our ﬁndings contribute to the wide body of evi-
dence that AECA from SSc patients target speciﬁc endothelial anti-
gens. In particular, we have shown here that SSc patient-derived
anti-ICAM-1 antibodies cause pro-inﬂammatory activation of human
endothelial cells, suggesting that they are not only a marker of disease
but that they contribute to its progression.cells. Puriﬁed anti-ICAM-1 antibodies, in the presence or absence of crosslinking RAH
nce staining for VCAM-1 and analysis by ﬂow cytometry. A. Representative (n = 6) histo-
treatedwith puriﬁed anti-ICAM-1 (diluted 1:100)with orwithout crosslinking. B. Percent-
ntrol), negative serum (diluted 1:100), wash buffer (diluted 1:100) with or without RAH
ith or without crosslinking. **p b 0.01, ***p b 0.001 compared to untreated cells. 1 way
CAM-1 expression after treatment with puriﬁed patient anti-ICAM-1 antibodies (diluted
TNF treatment 18 h (n = 2 HUVEC isolates) (Friedman ANOVA for non-parametric data
crosslinked puriﬁed Ab 12 h, 18 h, or 24 h). D. Concentration effect of puriﬁed patient
g on VCAM-1 expression in HUVEC or VCAM-1 staining after TNF treatment 18 h
post-test comparison *p b 0.05 crosslinked puriﬁed Ab diluted 1:100 compared to
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